{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:21:36Z","timestamp":1778170896498,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,5]]},"DOI":"10.7759\/cureus.68748","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T02:59:20Z","timestamp":1725591560000},"source":"Crossref","is-referenced-by-count":6,"title":["A Comprehensive Review of Low-Dose Interleukin-2 (IL-2) Therapy for Systemic Lupus Erythematosus: Mechanisms, Efficacy, and Clinical Applications"],"prefix":"10.7759","author":[{"given":"Amna","family":"Farooq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubam","family":"Trehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurjot","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prateek","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Bector","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayush","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajpreet S","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos GC","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011, 365:2110-21. 10.1056\/NEJMra1100359","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman A","year":"2008","unstructured":"Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008, 358:929-39. 10.1056\/NEJMra071297","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.007","article-title":"Understanding the epidemiology and progression of systemic lupus erythematosus","volume":"39","author":"Pons-Estel GJ","year":"2010","unstructured":"Pons-Estel GJ, Alarc\u00f3n GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010, 39:257-68. 10.1016\/j.semarthrit.2008.10.007","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.38238","article-title":"Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program","volume":"66","author":"Somers EC","year":"2014","unstructured":"Somers EC, Marder W, Cagnoli P, et al.. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis Rheumatol. 2014, 66:369-78. 10.1002\/art.38238","journal-title":"Arthritis Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber MR","year":"2021","unstructured":"Barber MR, Drenkard C, Falasinnu T, et al.. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021, 17:515-32. 10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/art.40512","article-title":"Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015","volume":"70","author":"Yen EY","year":"2018","unstructured":"Yen EY, Singh RR. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000-2015. Arthritis Rheumatol. 2018, 70:1251-5. 10.1002\/art.40512","journal-title":"Arthritis Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn BH","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, et al.. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012, 64:797-808. 10.1002\/acr.21664","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias GK","year":"2010","unstructured":"Bertsias GK, Ioannidis JP, Aringer M, et al.. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010, 69:2074-82. 10.1136\/ard.2010.130476","journal-title":"Ann Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0188-0","article-title":"B cells and autoimmune diseases: regulatory roles of TLRs","volume":"13","author":"Lipsky PE","year":"2011","unstructured":"Lipsky PE, Tao XG. B cells and autoimmune diseases: regulatory roles of TLRs. Current Rheumatology Reports. 2011, 13:377-85. 10.1007\/s11926-011-0188-0","journal-title":"Current Rheumatology Reports"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra SV","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al.. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011, 377:721-31. 10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill JT","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, et al.. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010, 62:222-33. 10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie R","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al.. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017, 69:376-86. 10.1002\/art.39962","journal-title":"Arthritis Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner T","year":"2019","unstructured":"D\u00f6rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019, 393:2344-58. 10.1016\/S0140-6736(19)30546-X","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann D","year":"2015","unstructured":"Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015, 15:283-94. 10.1038\/nri3823","journal-title":"Nat Rev Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins MB","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, et al.. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999, 17:2105-16. 10.1200\/JCO.1999.17.7.2105","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-055756","article-title":"Nonredundant roles for Stat5a\/b in directly regulating Foxp3","volume":"109","author":"Yao Z","year":"2007","unstructured":"Yao Z, Kanno Y, Kerenyi M, et al.. Nonredundant roles for Stat5a\/b in directly regulating Foxp3. Blood. 2007, 109:4368-75. 10.1182\/blood-2006-11-055756","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090547","article-title":"FOXP3: of mice and men","volume":"24","author":"Ziegler SF","year":"2006","unstructured":"Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006, 24:209-26. 10.1146\/annurev.immunol.24.021605.090547","journal-title":"Annu Rev Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and function of interleukin-2 in T lymphocytes","volume":"36","author":"Ross SH","year":"2018","unstructured":"Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018, 36:411-33. 10.1146\/annurev-immunol-042617-053352","journal-title":"Annu Rev Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He J","year":"2020","unstructured":"He J, Zhang R, Shao M, et al.. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020, 79:141-9. 10.1136\/annrheumdis-2019-215396","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi S","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008, 133:775-87. 10.1016\/j.cell.2008.05.009","journal-title":"Cell"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/08916931003782114","article-title":"Regulatory immune cell subsets in autoimmunity","volume":"44","author":"La Cava A","year":"2011","unstructured":"La Cava A. Regulatory immune cell subsets in autoimmunity. Autoimmunity. 2011, 44:1-2. 10.3109\/08916931003782114","journal-title":"Autoimmunity"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth J","year":"2011","unstructured":"Koreth J, Matsuoka K, Kim HT, et al.. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011, 365:2055-66. 10.1056\/NEJMoa1108188","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nri1435","article-title":"Tolerance, not immunity, crucially depends on IL-2","volume":"4","author":"Malek TR","year":"2004","unstructured":"Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004, 4:665-74. 10.1038\/nri1435","journal-title":"Nat Rev Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman O","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012, 12:180-90. 10.1038\/nri3156","journal-title":"Nat Rev Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00620-7","article-title":"Efficacy, safety and the lymphocyte subset changes of low-dose IL-2 in patients with autoimmune rheumatic diseases: a systematic review and meta-analysis","volume":"11","author":"Su Q","year":"2024","unstructured":"Su Q, Wang X, Li Y, et al.. Efficacy, safety and the lymphocyte subset changes of low-dose IL-2 in patients with autoimmune rheumatic diseases: a systematic review and meta-analysis. Rheumatol Ther. 2024, 11:79-96. 10.1007\/s40744-023-00620-7","journal-title":"Rheumatol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1165","article-title":"Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"12","author":"Su QY","year":"2024","unstructured":"Su QY, Luo J, Wang XM, Di JK, Cao YX, Zhang SX. Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Immun Inflamm Dis. 2024, 12:e1165. 10.1002\/iid3.1165","journal-title":"Immun Inflamm Dis"},{"key":"ref27","article-title":"Low-dose interleukin-2 therapy in SLE: preclinical evidence, mechanistic insights, and early clinical experience","volume":"24","author":"Humrich JY","year":"2015","unstructured":"Humrich JY, Spee-Mayer CV, Siegert E, et al.. Low-dose interleukin-2 therapy in SLE: preclinical evidence, mechanistic insights, and early clinical experience. Lupus. 2015, 24:499-507.","journal-title":"Lupus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213844","article-title":"Inconsistency between supplement and article?","volume":"78","author":"Babaoglu H","year":"2019","unstructured":"Babaoglu H. Inconsistency between supplement and article?. Ann Rheum Dis. 2019, 78:e84. 10.1136\/annrheumdis-2018-213844","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/283684-a-comprehensive-review-of-low-dose-interleukin-2-il-2-therapy-for-systemic-lupus-erythematosus-mechanisms-efficacy-and-clinical-applications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T02:59:23Z","timestamp":1725591563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/283684-a-comprehensive-review-of-low-dose-interleukin-2-il-2-therapy-for-systemic-lupus-erythematosus-mechanisms-efficacy-and-clinical-applications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.68748","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}